Cabaletta Bio, Inc. - Common Stock (CABA)

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight.

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.

Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.

In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.

As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

The company announced the addition of two subtype-specific cohorts to its RESET-Myositis trial and received RMAT designation from the FDA for rese-cel.

Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

U.S. stock futures advanced on Friday after a day's break for Thanksgiving as investors look to end November on a high note.

CABA stock results show that Cabaletta Bio missed analyst estimates for earnings per share the second quarter of 2024.

CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's remarkable remission. This breakthrough offers new hope for autoimmune disease patients but faces challenges in cost and manufacturing.